Who Is Buying Vertex Pharmaceuticals? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding Vertex Pharmaceuticals (VRTX) based on latest 13F filings. D.E. Shaw exits, Two Sigma enters — a major institutional rotation.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying Vertex Pharmaceuticals? Hedge Fund Activity in 2026
Vertex Pharmaceuticals has built an extraordinary franchise around cystic fibrosis (CF), dominating the market with Trikafta — a drug so effective that it essentially transformed CF from a fatal disease into a manageable condition. But Vertex's ambitions extend far beyond CF. The company is aggressively expanding into pain (with the non-opioid VX-548), gene editing (through its Casgevy partnership with CRISPR Therapeutics), kidney disease, and other rare conditions. This pipeline evolution has turned Vertex from a one-drug company into a diversified biotech platform.
The latest 13F filings show a mildly bearish tilt: 5 funds buying versus 6 selling, with 5 holding steady across 16 tracked funds. But the headline that grabs attention is a dramatic exit-and-entry swap between two major quant funds.
Quick Answer
Across the funds we read directly from SEC filings, the largest Vertex Pharmaceuticals position in the Q2 2026 13Fs (period ending 30 June 2026) is Citadel Advisors at $254M (510,430 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Renaissance Technologies, where Vertex Pharmaceuticals is 0.2% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
Vertex Pharmaceuticals Institutional Snapshot
| Metric | Value |
|---|---|
| Funds Buying | 5 |
| Funds Selling | 6 |
| Funds Holding | 5 |
| Active Funds Tracked | 16 |
A 5-to-6 buy-sell ratio is slightly bearish, but the story is more complex than the numbers suggest. The buying side includes massive institutional positions from State Street and specialized biotech conviction from Baker Bros. The selling side features notable reductions from Vanguard and Fidelity — an unusual alignment.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeWho holds Vertex Pharmaceuticals, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Citadel Advisors | $254M | 510,430 | 0.1% of $171.84B |
| Millennium Management | $233M | 468,410 | 0.2% of $142.92B |
| Renaissance Technologies | $159M | 320,008 | 0.2% of $72.62B |
| Bridgewater Associates | $5.4M | 10,865 | 0.0% of $24.38B |
The last column is the one worth reading. A multi-strategy fund reporting a $100B+ book can hold a large dollar amount of Vertex Pharmaceuticals that means almost nothing to it, while a concentrated fund holding less in dollars may have several percent of its entire book in the name. Rankings by dollar value hide exactly that difference.
Who added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Millennium Management | 30,823 | 468,410 | +1420% |
| Citadel Advisors | 339,298 | 510,430 | +50% |
| Renaissance Technologies | 421,688 | 320,008 | -24% |
| Bridgewater Associates | 13,357 | 10,865 | -19% |
A fund absent from this table reported no Vertex Pharmaceuticals position in either quarter.
Related Articles
- Who Is Buying Moderna? Hedge Fund Activity in 2026
- Who Is Buying Gilead Sciences? Hedge Fund Activity in 2026
- Who Is Buying Regeneron? Hedge Fund Activity in 2026
FAQ
Why is Vertex's cystic fibrosis franchise both a strength and a risk?
The CF franchise, anchored by Trikafta, generates strong recurring revenue and high margins because of Vertex's dominant market position in a well-defined patient population. The risk is that the addressable CF population is finite, so future growth depends increasingly on pipeline assets outside CF rather than franchise expansion.
What is the significance of suzetrigine (VX-548) for institutional investors?
Suzetrigine is Vertex's non-opioid pain candidate and represents one of the largest potential new markets for the company. Funds adding to VRTX appear to be assigning meaningful value to a successful commercial ramp in acute and potentially chronic pain, while sellers may be discounting regulatory or adoption risk.
How does the Casgevy gene therapy partnership factor into the thesis?
Casgevy, developed with CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassemia, validates Vertex's expansion into gene editing platforms. Institutional investors typically frame Casgevy as long-duration optionality rather than a near-term earnings driver, given the operational complexity of one-time gene therapies.
Why did D.E. Shaw exit while Two Sigma initiated a new position?
The swap reflects genuine model disagreement between two leading quantitative funds on Vertex's near-term setup. Different factor weightings, signal horizons, and risk constraints can produce opposite recommendations on the same name, which often coincides with periods of elevated stock-specific volatility.
What should long-term holders watch in Vertex's pipeline?
Key items include suzetrigine label expansion data, real-world Casgevy uptake metrics, progress on the kidney disease and type 1 diabetes programs, and updates on next-generation CF candidates. These data points will shape whether the institutional debate resolves bullish or bearish over future 13F cycles.